Citations (59)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (20)
Daniel C. Beachler, Gail Fernandes, Gaurav Deshpande, Jamileh Jemison, Jennifer G. Lyons, Stephan Lanes, Jinan Liu & Annie McNeill. (2018) Patient and prescriber characteristics among patients with type 2 diabetes mellitus continuing or discontinuing sulfonylureas following insulin initiation: data from a large commercial database. Current Medical Research and Opinion 34:6, pages 1061-1069.
Read now
Read now
Wendy S. Lane, James Weatherall, Jens Gundgaard & Richard F. Pollock. (2018) Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables. Journal of Medical Economics 21:2, pages 144-151.
Read now
Read now
Jieruo Liu, Rosa Wang, Michael L. Ganz, Yurek Paprocki, Doron Schneider & James Weatherall. (2018) The burden of severe hypoglycemia in type 2 diabetes. Current Medical Research and Opinion 34:1, pages 179-186.
Read now
Read now
Mirko V Sikirica, Alan A Martin, Robert Wood, Andrea Leith, James Piercy & Victoria Higgins. (2017) Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 10, pages 403-412.
Read now
Read now
James Weatherall, Lisa Bloudek & Sarah Buchs. (2017) Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine. Current Medical Research and Opinion 33:2, pages 231-238.
Read now
Read now
Volker Foos, Nebibe Varol, Bradley H. Curtis, Kristina S. Boye, David Grant, James L. Palmer & Phil McEwan. (2015) Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States. Journal of Medical Economics 18:6, pages 420-432.
Read now
Read now
Stuart Samuel, Devesh Goswami, Kenny Shum, Kristina S. Boye, Badri Rengarajan, Bradley Curtis & Sarah E. Curtis. (2015) A model of mild hypoglycemia. Current Medical Research and Opinion 31:4, pages 633-641.
Read now
Read now
Michael L. Ganz, Neil S. Wintfeld, Qian Li, Yuan-Chi Lee, Elyse Gatt & Joanna C. Huang. (2014) Severe hypoglycemia rates and associated costs among type 2 diabetics starting basal insulin therapy in the United States. Current Medical Research and Opinion 30:10, pages 1991-2000.
Read now
Read now
Sheila A Doggrell. (2013) Exenatide extended-release; clinical trials, patient preference, and economic considerations. Patient Preference and Adherence 7, pages 35-45.
Read now
Read now
Claes-Göran Östenson, Stephan Matthaei, Matthew Reaney, Thure Krarup, Bruno Guerci, Jacek Kiljanski, Carole Salaun-Martin, Hélène Sapin, David Bruhn, Chantal Mathieu & Michael Theodorakis. (2013) Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries. Diabetes, Metabolic Syndrome and Obesity 6, pages 171-185.
Read now
Read now
Daniel A. Nadeau. (2013) Physiologic and Weight-Focused Treatment Strategies for Managing Type 2 Diabetes Mellitus: The Metformin, Glucagon-Like Peptide-1 Receptor Agonist, and Insulin (MGI) Approach. Postgraduate Medicine 125:3, pages 112-126.
Read now
Read now
Meryl Brod, Azhar Rana & Anthony H. Barnett. (2012) Adherence patterns in patients with type 2 diabetes on basal insulin analogues: missed, mistimed and reduced doses. Current Medical Research and Opinion 28:12, pages 1933-1946.
Read now
Read now
Eric Q. Wu, Steve Zhou, Andrew Yu, Mei Lu, Hari Sharma, Jasvinder Gill & Thomas Graf. (2012) Outcomes Associated with Post-Discharge Insulin Continuity in US Patients with Type 2 Diabetes Mellitus Initiating Insulin in the Hospital. Hospital Practice 40:4, pages 40-48.
Read now
Read now
Morgan Bron, Maryna Marynchenko, Hongbo Yang, Andrew P. Yu & Eric Q. Wu. (2012) Hypoglycemia, Treatment Discontinuation, and Costs in Patients with Type 2 Diabetes Mellitus on Oral Antidiabetic Drugs. Postgraduate Medicine 124:1, pages 124-132.
Read now
Read now
Richard M. Bergenstal, Louis P. Garrison$suffix/text()$suffix/text(), Lesley-Ann Miller, Likun Hou, Amy Blickensderfer, Anthony Zagar, Shelley Stanley, Anuj Bhargava, Rolin Wade & William H. Herman. (2011) Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting. Current Medical Research and Opinion 27:12, pages 2335-2342.
Read now
Read now
Richard M. Bergenstal, Louis P. Garrison$suffix/text()$suffix/text(), Matthew Wintle, Amy Blickensderfer, Rolin Wade, Likun Hou, Lesley-Ann Miller, Jamie Scism-Bacon, Anthony Zagar, Derek Misurski & William H. Herman. (2011) Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting. Current Medical Research and Opinion 27:3, pages 531-540.
Read now
Read now
Onur Baser, Wenhui Wei, Erdem Baser & Lin Xie. (2011) Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID. Journal of Medical Economics 14:6, pages 673-680.
Read now
Read now
Machaon MK Bonafede, Anupama Kalsekar, Manjiri Pawaskar, Kimberly M Ruiz, Amelito M Torres, Karen R Kelly & Suellen M Curkendall. (2010) A retrospective database analysis of insulin use patterns in insulin-naïve patients with type 2 diabetes initiating basal insulin or mixtures. Patient Preference and Adherence 4, pages 147-156.
Read now
Read now
Thomas Blevins, Jenny Han, Dawn Nicewarner, Steve Chen, Juliana H. A. Oliveira & Stephen Aronoff. (2010) Exenatide is Non-inferior to Insulin in Reducing HbA1c: An Integrated Analysis of 1423 Patients with Type 2 Diabetes. Postgraduate Medicine 122:3, pages 118-128.
Read now
Read now
Carol H. Wysham. (2010) New Perspectives in Type 2 Diabetes, Cardiovascular Risk, and Treatment Goals. Postgraduate Medicine 122:3, pages 52-60.
Read now
Read now
Articles from other publishers (39)
Hanxi ZhangJamie C BarnerLeticia R MoczygembaKaren L Rascati. (2020) Assessment of basal insulin adherence using 2 methodologies among Texas Medicaid enrollees with type 2 diabetes. Journal of Managed Care & Specialty Pharmacy 26:11, pages 1434-1444.
Crossref
Crossref
Li Wang, Xiangyang Liu, Wenjuan Yang, Jingbo Lai, Xinwen Yu, Jianrong Liu, Xiling Gao, Jie Ming, Kaiyan Ma, Jing Xu, Zhufang Tian, Qingzhen He & Qiuhe Ji. (2020) Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter, Open-Label, Randomized Trial. Diabetes Therapy 11:10, pages 2313-2328.
Crossref
Crossref
Thomas Wilke, Sabrina Mueller, Andreas Fuchs, Margit S. Kaltoft, Stefan Kipper & Malgorzata Cel. (2020) Diabetes-Related Effectiveness and Cost of Liraglutide or Insulin in German Patients with Type 2 Diabetes: A 5-Year Retrospective Claims Analysis. Diabetes Therapy 11:10, pages 2357-2370.
Crossref
Crossref
Asnakew Achaw Ayele, Henok Getachew Tegegn, Tadesse Awoke Ayele & Mohammed Biset Ayalew. (2019) Medication regimen complexity and its impact on medication adherence and glycemic control among patients with type 2 diabetes mellitus in an Ethiopian general hospital. BMJ Open Diabetes Research & Care 7:1, pages e000685.
Crossref
Crossref
Takahiro Takase, Akinobu Nakamura, Chiho Yamamoto, Hiroshi Nomoto, Aika Miya, Midori Dannoura, Kyu Yong Cho, Yoshio Kurihara, Naoki Manda, Shin Aoki, Tatsuya Atsumi & Hideaki Miyoshi. (2018) Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial. Journal of Diabetes Investigation 10:3, pages 699-705.
Crossref
Crossref
Cherlie Magny-Normilus, Nyryan V. Nolido, Jorge C. Borges, Maureen Brady, Stephanie Labonville, Deborah Williams, Jane Soukup, Stuart Lipsitz, Margo Hudson & Jeffrey L. Schnipper. (2019) Effects of an Intensive Discharge Intervention on Medication Adherence, Glycemic Control, and Readmission Rates in Patients With Type 2 Diabetes. Journal of Patient Safety Publish Ahead of Print.
Crossref
Crossref
Priti P. Pednekar, Tamás Ágh, Maria Malmenäs, Amit D. Raval, Bryan M. Bennett, Bijan J. Borah, David S. Hutchins, Elizabeth Manias, Allison F. Williams, Mickaël Hiligsmann, Adina Turcu-Stiolica, John E. Zeber, Lusine Abrahamyan, Thomas J. Bunz & Andrew M. Peterson. (2019) Methods for Measuring Multiple Medication Adherence: A Systematic Review–Report of the ISPOR Medication Adherence and Persistence Special Interest Group. Value in Health 22:2, pages 139-156.
Crossref
Crossref
S. Halimi. (2018) Diabète de type 2 : observance thérapeutique aux nouveaux antidiabétiques. Médecine des Maladies Métaboliques 12:6, pages 487-495.
Crossref
Crossref
Cristiano S. Moura, Zale B. Rosenberg, Michal Abrahamowicz, Sasha Bernatsky, Hassan Behlouli & Louise Pilote. (2018) Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy. Journal of Diabetes Research 2018, pages 1-7.
Crossref
Crossref
Shuyan Gu, Xiaoyong Wang, Qing Qiao, Weiguo Gao, Jian Wang & Hengjin Dong. (2017) Cost‐effectiveness of exenatide twice daily vs insulin glargine as add‐on therapy to oral antidiabetic agents in patients with type 2 diabetes in China. Diabetes, Obesity and Metabolism 19:12, pages 1688-1697.
Crossref
Crossref
Maria Yu, Reema Mody, Laura Fernández Landó, Amy Shui, Lee Kallenbach, Lukas Slipski & Carolina Piras de Oliveira. (2017) Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes. Clinical Therapeutics 39:12, pages 2399-2408.
Crossref
Crossref
Samuel StolpeMichel A. KroesNeil WebbTami Wisniewski. (2016) A Systematic Review of Insulin Adherence Measures in Patients with Diabetes. Journal of Managed Care & Specialty Pharmacy 22:11, pages 1224-1246.
Crossref
Crossref
Qing Qiao, Susan Grandy, Josh Hiller & Karel Kostev. (2016) Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany. PLOS ONE 11:3, pages e0152281.
Crossref
Crossref
Thomas Wilke, Sabrina Mueller, Antje Groth, Bjoern Berg, Andreas Fuchs, Mirko Sikirica, John Logie, Alan Martin & Ulf Maywald. (2015) Non-Persistence and Non-Adherence of Patients with Type 2 Diabetes Mellitus in Therapy with GLP-1 Receptor Agonists: A Retrospective Analysis. Diabetes Therapy 7:1, pages 105-124.
Crossref
Crossref
Sang Youl Rhee, Soo Min Hong, Suk Chon, Kyu Jeung Ahn, Sung Hoon Kim, Sei Hyun Baik, Yong Soo Park, Moon Suk Nam, Kwan Woo Lee, Jeong-Taek Woo & Young Seol Kim. (2016) Hypoglycemia and Medical Expenses in Patients with Type 2 Diabetes Mellitus: An Analysis Based on the Korea National Diabetes Program Cohort. PLOS ONE 11:2, pages e0148630.
Crossref
Crossref
Kam CapocciaPeggy S. OdegardNancy Letassy. (2015) Medication Adherence With Diabetes Medication. The Diabetes Educator 42:1, pages 34-71.
Crossref
Crossref
Philip Levin, Steve Zhou, Emily Durden, Amanda M. Farr, Jasvinder Gill & Wenhui Wei. (2016) Clinical and Economic Outcomes Associated With the Timing of Initiation of Basal Insulin in Patients With Type 2 Diabetes Mellitus Previously Treated With Oral Antidiabetes Drugs. Clinical Therapeutics 38:1, pages 110-121.
Crossref
Crossref
Paul L. McCormack. (2014) Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus. Drugs 74:3, pages 325-351.
Crossref
Crossref
Manjiri Pawaskar, Machaon Bonafede, Barbara Johnson, Robert Fowler, Gregory Lenhart & Byron Hoogwerf. (2013) Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study. BMC Endocrine Disorders 13:1.
Crossref
Crossref
Jaime A. Davidson. (2013) Incretin-Based Therapies: Focus on Effects Beyond Glycemic Control Alone. Diabetes Therapy 4:2, pages 221-238.
Crossref
Crossref
Robert R. Henry, Julio Rosenstock, Douglas K. Logan, Thomas R. Alessi, Kenneth Luskey & Michelle A. Baron. (2013) Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes. Diabetes Care 36:9, pages 2559-2565.
Crossref
Crossref
P Karagianni, SA Polyzos, N Kartali, I Zografou & C Sambanis. (2013) Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy. Advances in Medical Sciences 58:1, pages 38-43.
Crossref
Crossref
Robert R. Henry, Douglas Logan, Thomas Alessi & Michelle A. Baron. (2013) A Randomized, Open-Label, Multicenter, 4-Week Study to Evaluate the Tolerability and Pharmacokinetics of ITCA 650 in Patients With Type 2 Diabetes☆☆This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.. Clinical Therapeutics 35:5, pages 634-645.e1.
Crossref
Crossref
Michael Cobble. (2012) Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome 4:1.
Crossref
Crossref
Stephan Matthaei, Matthew Reaney, Chantal Mathieu, Claes-Göran Östenson, Thure Krarup, Bruno Guerci, Jacek Kiljanski, Helmut Petto, David Bruhn & Michael Theodorakis. (2012) Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study. Diabetes Therapy 3:1.
Crossref
Crossref
Eric Q. Wu, Steve Zhou, Andrew Yu, Mei Lu, Hari Sharma, Jasvinder Gill & Thomas Graf. (2012) Outcomes Associated With Insulin Therapy Disruption After Hospital Discharge Among Patients with Type 2 Diabetes Mellitus who Had Used Insulin Before and During Hospitalization. Endocrine Practice 18:5, pages 651-659.
Crossref
Crossref
M. Pawaskar, Q. Li, B. J. Hoogwerf, M. W. Reynolds, D. Faries, W. Engelman, D. Bruhn & R. M. Bergenstal. (2012) Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting. Diabetes, Obesity and Metabolism 14:7, pages 626-633.
Crossref
Crossref
Mariano de la Figuera. (2012) Métodos de medida del cumplimiento terapéutico en la diabetes tipo 2. Hipertensión y Riesgo Vascular 29, pages 14-19.
Crossref
Crossref
Emilio Márquez Contreras. (2012) El incumplimiento en el tratamiento de la diabetes mellitus tipo 2 en España. Hipertensión y Riesgo Vascular 29, pages 8-13.
Crossref
Crossref
J. H. Best, K. Lavillotti, M. B. DeYoung & L. P. Garrison. (2011) The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review. Diabetes, Obesity and Metabolism 14:5, pages 387-398.
Crossref
Crossref
Nazia Rashid, Jeffrey S. McCombs & Elizabeth Schwartz. (2012) Effect of Exenatide, Pen Insulin, and Vial Insulin on Patient Outcomes: A Retrospective Database Analysis of Persistence and First-Year Costs in a Commercially Insured Population. Clinical Therapeutics 34:5, pages 1145-1158.
Crossref
Crossref
Emilio Márquez Contreras, Nieves Martell Claros, Vicente Gil Guillén, José Joaquín Casado Martínez, José Luis Martín de Pablos, Javier Ferraro García, Rosa Chaves González & Amalia Fernández Ortega. (2012) El cumplimiento terapéutico con insulina en el tratamiento de la diabetes mellitus tipo 2: estudio CUMINDIAB. Atención Primaria 44:2, pages 74-81.
Crossref
Crossref
Machaon M Bonafede, Anupama Kalsekar, Manjiri Pawaskar, Kimberly M Ruiz, Amelito M Torres, Karen R Kelly & Suellen M Curkendall. (2011) Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: a retrospective database analysis. BMC Endocrine Disorders 11:1.
Crossref
Crossref
Scott V. Joy, Jeffrey S. Freeman & James R. LaSalle. (2011) Tailoring treatment for type 2 diabetes: Uncovering the HOW and NOW of GLP-1 receptor agonist therapy. Osteopathic Family Physician 3:5, pages 217-236.
Crossref
Crossref
María Costi, Helen Smith, Jesús Reviriego, Conxa Castell, Alberto Goday & Tatiana Dilla. (2011) Costes directos sanitarios en pacientes con diabetes mellitus tipo 2 a los seis meses de inicio del tratamiento con insulina en España: estudio INSTIGATE. Endocrinología y Nutrición 58:6, pages 274-282.
Crossref
Crossref
Nian Gong, Ai‐Niu Ma, Li‐Jie Zhang, Xiao‐Su Luo, Yin‐Hui Zhang, Michael Xu & Yong‐Xiang Wang. (2011) Site‐specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity. British Journal of Pharmacology 163:2, pages 399-412.
Crossref
Crossref
R. Keith Campbell. (2011) Clarifying the Role of Incretin-Based Therapies in the Treatment of Type 2 Diabetes Mellitus. Clinical Therapeutics 33:5, pages 511-527.
Crossref
Crossref
Mar?a Costi, Helen Smith, Jes?s Reviriego, Conxa Castell, Alberto Goday & Tatiana Dilla. (2011) Direct health care costs in patients with type 2 diabetes mellitus six months after starting insulin treatment in Spain: The INSTIGATE Study. Endocrinolog?a y Nutrici?n (English Edition) 58:6, pages 274-282.
Crossref
Crossref
Louis Kuritzky. (2010) Managing Type 2 Diabetes in the Primary Care Setting: Beyond Glucocentricity. The American Journal of the Medical Sciences 340:2, pages 133-143.
Crossref
Crossref